Dei BioPharma’s Dr. Magoola wins African Excellence Award for biotech innovation

UGANDA—Dr. Matthias Magoola, the founder and Managing Director of Dei Biopharma Ltd, has been honoured as a distinguished recipient of the African Excellence & Personality Awards 2025.

This recognition comes just a few months after Dr. Magoola received accolades for his contributions to vaccine research at the prestigious International Molecular Biologist Awards in December 2024.

He was awarded the Best Researcher Award for his innovative work in using mRNA technology to develop therapeutic drugs and protein vaccines.

This latest accolade, celebrated across the continent, highlights Dr. Magoola’s visionary leadership and groundbreaking innovations in sectors vital to Africa’s progress, particularly in economic development and healthcare transformation.

Dr. Magoola’s commitment to advancing biotechnology and pharmaceuticals has established a new standard for self-reliance within Africa’s healthcare sector.

His relentless efforts and forward-thinking approach have improved public health outcomes and positioned him among the continent’s most influential figures.

The award underscores the importance of scientific research and technological innovation in tackling some of Africa’s most pressing challenges.

In an official statement, Dei Group International congratulated Dr. Magoola, emphasizing that his leadership continues to redefine the potential of Africa’s biotech and pharmaceutical industries.

The organization highlighted how his work has been instrumental in driving significant advancements that enhance public health and contribute to the broader economic growth of the region.

 This recognition is not only a personal achievement for Dr. Magoola; it also reflects the collective progress of the African scientific community.

Dei BioPharma’s Vision for Uganda

In February, H.E. President Yoweri Museveni recognized Dei BioPharma Ltd. for its pioneering efforts to promote Uganda’s self-sufficiency in pharmaceutical manufacturing.

During the ceremony, the President stated, “Dei BioPharma in Matugga is now at the manufacturing stage for 30 different drugs, vaccines, and various antibiotics.”

This commendation from the nation’s highest office highlights the strategic importance of local innovation for the future of health in the country.

Looking ahead, Dei BioPharma is committed to enhancing Uganda’s self-reliance by launching an ambitious project to produce one billion doses of mRNA vaccines.

This initiative will meet the stringent international standards set by organizations such as the World Health Organization, the U.S. Food and Drug Administration, and the European Medicines Agency.

The project is expected to generate local job opportunities, develop domestic talent, and stimulate economic growth.

Moreover, the company recently celebrated a significant milestone with the development of a vaccine for Foot and Mouth Disease (FMD), which was marked by the approval of Dr. Magoola’s patent by the U.S. Patent Office.

Commenting on these remarkable achievements, Dr. Magoola stressed that President Museveni’s recognition is a powerful reminder of the vital role that scientific innovation plays in transforming public health.

He reiterated his commitment to developing innovative solutions that address Uganda’s health challenges, emphasizing that such efforts are essential for sustainable development and improved quality of life across Africa.